Literature DB >> 3006606

Leukopheresis for treatment of psoriasis: is therapeutical benefit related to reduced activities of neutral proteinases of polymorphonuclear leukocytes?

W Gliński, D Barszcz, S Jabłońska, Z Zarebska, M Tigałonowa, E Janczura.   

Abstract

Ten patients were treated with repeated leukophereses performed one to three times per week for 2-5 weeks. Two of the patients was cleared completely, four exhibited regression of more than one-half of the lesions, and four showed only a slight improvement. The therapy did not markedly affect the granulocyte count in peripheral blood, and the beneficial clinical response was not related to the number of polymorphonuclear leukocytes (PMNs) removed by leukophereses. During therapy, the activities of elastase, cathepsin G, lysozyme, and myeloperoxidase in PMNs were determined by spectrophotometry. PMNs isolated using a Haemonetics 30 blood-cell separator were about 50% deficient in these activities in comparison to cells obtained directly from peripheral blood. Thus, leukopheresis induces a marked degranulation of PMNs. Repeated leukophereses were found to generate significant variations in the activities of circulating PMN granule enzymes and in the levels of acid-soluble proteins. Remission or great improvement were observed in patients who, during therapy, exhibited decreased PMN elastase and cathepsin G activities, whereas a poor clinical response was accompanied by high enzymatic activities.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3006606     DOI: 10.1007/bf00412488

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  21 in total

1.  Enhanced chemotactic and phagocytic activities of leukocytes in psoriasis vulgaris.

Authors:  A Wahba; H A Cohen; M Bar-Eli; R Gallily
Journal:  J Invest Dermatol       Date:  1978-09       Impact factor: 8.551

2.  Dialysis for psoriasis.

Authors:  P C Anderson
Journal:  Artif Organs       Date:  1978-05       Impact factor: 3.094

3.  Psoriatic clearance during haemodialysis.

Authors:  J McEvoy; A M Kelly
Journal:  Ulster Med J       Date:  1976

4.  Peritoneal dialysis for psoriasis. An uncontrolled study.

Authors:  Z J Twardowski; K D Nolph; J Rubin; P C Anderson
Journal:  Ann Intern Med       Date:  1978-03       Impact factor: 25.391

5.  Neutral proteinases and other neutrophil enzymes in psoriasis, and their relation to disease activity.

Authors:  W Gliński; D Barszcz; E Janczura; Z Zarebska; S Jabłońska
Journal:  Br J Dermatol       Date:  1984-08       Impact factor: 9.302

6.  On the mechanism of enhanced monocyte and neutrophil cytotoxicity in severe psoriasis.

Authors:  T Herlin; N Borregaard; K Kragballe
Journal:  J Invest Dermatol       Date:  1982-08       Impact factor: 8.551

7.  The effect of hemodialysis on neutrophil chemotactic responsiveness.

Authors:  W H Greene; C Ray; S M Mauer; P G Quie
Journal:  J Lab Clin Med       Date:  1976-12

8.  Increased granulocyte adherence in psoriasis and psoriatic arthritis.

Authors:  J B Sedgwick; P R Bergstresser; E R Hurd
Journal:  J Invest Dermatol       Date:  1980-02       Impact factor: 8.551

9.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.

Authors:  P R Craddock; J Fehr; A P Dalmasso; K L Brighan; H S Jacob
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  RNA and protein synthesis in human peripheral blood polymorphonuclear leukocytes.

Authors:  A Granelli-Piperno; J D Vassalli; E Reich
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

View more
  1 in total

1.  Alpha 1-proteinase inhibitor in psoriasis: reduced activity in symptom-free patients and during flare.

Authors:  D Barszcz; Z Zarebska; M Glińska-Ferenz; S Jabłońska; M Tigałonowa; W Gliński
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.